Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).
EURneffy is the first needle-free adrenaline treatment option in the EU, offering a more convenient and accessible alternative for adults and children with severe allergies.
It represents the first novel adrenaline delivery method in more than three decades, according to Richard Lowenthal, co-founder, president and CEO of ARS Pharma.
ARS Pharma anticipates that EURneffy will be available to patients in certain European Union member states in the fourth quarter of 2024.
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial